Speaking to NutraIngredients at Probiota Americas 2026, Caroline Carralero, founder of Daily Nouri, said growing understanding of the estrobolome is changing how the industry approaches women’s health, moving beyond broad probiotic positioning toward targeted interventions designed to support women through different hormonal life stages.
The estrobolome gains industry attention
Interest in the estrobolome, the gut microbiome’s role in estrogen metabolism, has accelerated as researchers investigate its influence on hormonal health.
Carralero said the growing body of research is encouraging companies to rethink how they develop products for women.
“Women don’t go through just one hormonal transition, we go through multiple hormonal transitions throughout our lives,” said Carralero.
She said that shift is prompting the industry to take a more targeted approach, recognizing that nutritional needs change from menstruation and fertility through pregnancy, postpartum recovery and menopause.
Carralero further explained that growing understanding is also changing how companies think about product development. Rather than formulating probiotics with broad wellness claims, she expects manufacturers to increasingly focus on strains selected for specific mechanisms of action and supported by evidence in clearly defined populations.
Clinical substantiation takes center stage
Carralero believes scientific validation will become increasingly important as women’s microbiome health continues to evolve.
She said the category is moving beyond broad microbiome claims and competition based on colony-forming unit (CFU) counts toward identifying strains that deliver measurable benefits for specific health outcomes.
“We’re moving away from asking whether probiotics work to understanding which strains work, for which outcomes, and why [and] clinical validation is becoming one of the biggest differentiators in this category,” she explained.
She said stronger evidence will be essential to building confidence among healthcare professionals and consumers as companies develop increasingly targeted women’s health solutions.
While research into the gut–hormone axis is still evolving, Carralero believes growing understanding of the estrobolome will increasingly shape how the industry approaches women’s health. The opportunity, she said, lies in combining targeted formulations with robust clinical evidence to better support women through specific hormonal life stages.
